与吸入性糖皮质激素使用相关的嗓音障碍
Voice Disorders Associated With the Use of Inhaled Corticosteroids.
作者信息
Naunheim Matthew R, Huston Molly N, Bhattacharyya Neil
机构信息
Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Department of Otolaryngology-Head and Neck Surgery, Washington University in St Louis, St Louis, Missouri, USA.
出版信息
Otolaryngol Head Neck Surg. 2023 May;168(5):1034-1037. doi: 10.1002/ohn.198. Epub 2023 Jan 24.
OBJECTIVE
Inhaled corticosteroids (ICS) have been demonstrated to be associated with voice changes. The goal was to determine the strength of the association between ICS use and a diagnosis of dysphonia made by an otolaryngologist and to determine whether inhaler particle type or medication type influenced this risk.
STUDY DESIGN
A case-control study from 2018 to 2020.
SETTING
Urban academic medical system.
METHODS
Adult patients with dysphonia diagnosed by an otolaryngologist, and control patients matched on age, gender, race, and health status, were included. Exposure to ICS was assessed, and the odds ratio (OR) of the association of ICS with dysphonia was calculated.
RESULTS
A total of 6551 cases and 6551 matched controls were included. We found that ICS use was significantly associated with dysphonia (OR: 5.11, 95% confidence interval: 4.23-6.17, p < .001). Subset analyses demonstrated no significant differences between inhaler particle types or specific active medications.
CONCLUSION
This study emphasizes the importance of identifying ICS use in the evaluation and treatment of patients with dysphonia.
目的
吸入性糖皮质激素（ICS）已被证明与嗓音变化有关。本研究旨在确定使用ICS与耳鼻喉科医生诊断的发声障碍之间关联的强度，并确定吸入器颗粒类型或药物类型是否会影响这种风险。
研究设计
一项2018年至2020年的病例对照研究。
研究地点
城市学术医疗系统。
方法
纳入由耳鼻喉科医生诊断为发声障碍的成年患者，以及在年龄、性别、种族和健康状况方面匹配的对照患者。评估ICS暴露情况，并计算ICS与发声障碍关联的比值比（OR）。
结果
共纳入6551例病例和6551例匹配对照。我们发现使用ICS与发声障碍显著相关（OR：5.11，95%置信区间：4.23 - 6.17，p <.001）。亚组分析表明，吸入器颗粒类型或特定活性药物之间无显著差异。
结论
本研究强调了在发声障碍患者的评估和治疗中识别ICS使用情况的重要性。
Zotero 插件